Primary Open-Angle Glaucoma

WAILEA, Hawaii — There is plenty of evidence in the literature to support reimbursement for goniotomy, according to a speaker at Hawaiian Eye 2024.

Skye Bioscience has treated the first patient in its phase 2 study of SBI-100 ophthalmic emulsion, a CB1 agonist delivered as an eye drop to treat patients with elevated IOP, according to a company press release.

NEW YORK — In this Healio Video Perspective from OSN New York, Susan Benton, president of Thea Pharma, discusses Iyuzeh for primary open-angle glaucoma. The treatment launched during the meeting.

Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle glaucoma or ocular hypertension.

MARCO ISLAND, Fla. — In this Healio Video Perspective, Monique M. Barbour, MD, MHA, FAAO, discusses why Iyuzeh is a promising new treatment for open-angle glaucoma and ocular hypertension.

VILAMOURA, Portugal — At the ESCRS winter meeting, Norbert Koerber, MD, PhD, presented the 5-year data of ab interno canaloplasty in patients with primary open-angle glaucoma.

Over the past 2 decades, a large body of research has shed light on the molecular determinants of many human disorders, including eye diseases.

Lack of treatment and poor patient compliance with medication are major concerns in the management of primary open-angle glaucoma, researchers reported in Patient Preference and Adherence.

An increased risk for primary open-angle glaucoma was found in individuals with higher systolic blood and pulse pressures, while no statistically significant link was found in those with elevations in diastolic or mean arterial pressures.

In my first year at a primary care and specialty referral practice in Memphis, Tennessee, I have treated patients at every stage of glaucoma.